Nanoparticles Enhance Treatment for Pulmonary Hypertension
Pulmonary hypertension is a serious, lifethreatening
disorder which substantially restricts physical capacities and results in a severely reduced life expectancy with an average survival time of only 2.8 years after diagnosis if the disease is not treated.<br> The new nanoparticles now allow a controlled release of inhalable active agents for pulmonary hypertension over a long period of time, thus leading to a prolongation of pharmacological effects and a considerably improved quality of patients' life.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
